Phase 3 Parkinson's Disease Trial, Recruiting NCT06345729 Sponsor: Merck Sharp & Dohme LLC Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 3 Parkinson's Disease Trial, Recruiting

NCT06345729
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with non-small cell lung cancer (a specific type of lung cancer), confirmed by a lab test on a tissue or cell sample.
  • Your lung cancer is either advanced (Stage IIIB or IIIC) and cannot be treated with surgery or chemotherapy/radiation to try to cure it, or it has spread to other parts of the body (Stage IV).
  • You are able to provide either a stored tumor tissue sample taken within the last 5 years, or a new tissue sample from a tumor that has not been previously treated with radiation, for laboratory testing.
  • If you had side effects from previous cancer treatments, those side effects have mostly or fully gone away.
  • If you have HIV, it is well managed with medication.
  • If you have Hepatitis B, you have been on treatment for it for at least 4 weeks and the virus is not detectable in your blood.
  • If you have a history of Hepatitis C, the virus is not currently detectable in your blood.

Who may not be able to join:

  • You have been diagnosed with small cell lung cancer, or your tumor contains any small cell elements.
  • You have active inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) that requires immune-suppressing medication, or you have a clear history of inflammatory bowel disease.
  • You have a known history of, or currently have, a nervous system condition caused by your cancer (known as a paraneoplastic syndrome) (confirm with trial site).
  • You currently have an active infection that requires treatment with medications taken throughout your body (such as antibiotics or antivirals).
  • You have serious, uncontrolled heart or blood vessel disease, or uncontrolled brain or stroke-related conditions.
  • You have certain eye conditions, including eye pressure above a certain level, glaucoma, specific retinal diseases, or other listed eye problems.
  • You have already received systemic (whole-body) cancer treatment for your advanced or metastatic lung cancer.
  • You have received high-dose radiation to your lungs within the past 6 months.
  • You have received any radiation therapy within the past 2 weeks, or have not fully recovered from its side effects.
  • You have active cancer that has spread to your brain or the lining around your brain and spinal cord.
  • You have another cancer that is growing or has needed active treatment within the past 3 years.
  • You have an autoimmune disease (where your immune system attacks your own body) that has needed systemic treatment within the past 2 years.
  • You have a history of, or currently have, lung inflammation or scarring (pneumonitis or interstitial lung disease) that required or requires steroid treatment.
  • You have HIV and also have a history of Kaposi's sarcoma or Multicentric Castleman's Disease.
  • You have had an organ or tissue transplant from another person.
  • You have not fully recovered from a recent major surgery.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Director, Merck Sharp & Dohme LLC

Phone: 1-888-577-8839

Australian sites

Chris O'Brien Lifehouse ( Site 3000), Camperdown, New South Wales
+61285140140
Cancer Care Service Hervey Bay ( Site 3003), Urraween, Queensland
+610743256110
Frankston Hospital ( Site 3002), Frankston, Victoria
+61397847777
One Clinical Research ( Site 3001), Nedlands, Western Australia
+61862799466

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
24 May 2024
Est. completion
19 February 2029

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇦🇹 Austria 🇧🇷 Brazil 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇱 Chile 🇨🇳 China 🇫🇷 France 🇬🇪 Georgia 🇩🇪 Germany 🇬🇷 Greece 🇮🇳 India 🇮🇹 Italy 🇯🇵 Japan 🇲🇽 Mexico 🇳🇱 Netherlands 🇳🇿 New Zealand 🇵🇭 Philippines 🇵🇱 Poland 🇷🇴 Romania 🇰🇷 South Korea 🇪🇸 Spain Turkey (Türkiye) 🇺🇦 Ukraine 🇬🇧 United Kingdom 🇺🇸 United States

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Progression-Free Survival (PFS); Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov